Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — November 2024

Genmab — November 2024

Planlagt Fastgjort Låst Flyttet Genmab
724 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • R Offline
    R Offline
    Raun
    wrote on sidst redigeret af
    #74

    Det kunne være dejligt at DK kører med på US optimisme. Men vi så faktisk lidt det samme billede mandag, og det var DK ret ligeglad med..... Men dog en dobbelt så stor omsætning ift. hvad US plejer...

    1 Reply Last reply
    0
    • SolsenS Offline
      SolsenS Offline
      Solsen
      wrote on sidst redigeret af
      #75

      Dette skulle være en konkurrent til Carvykti https://finance.yahoo.com/news/arcellx-present-clinical-data-phase-140000917.html

      1 Reply Last reply
      0
      • BulderB Offline
        BulderB Offline
        Bulder
        wrote on sidst redigeret af
        #76

        Ja, det er jo imponerende responser i 4. linje eller senere. Kan erzo næppe hamle op med.

        1 Reply Last reply
        0
        • SolsenS Offline
          SolsenS Offline
          Solsen
          wrote on sidst redigeret af
          #77

          Næppe. Men hvor stor en kapacitet kan man opstille til CAR-T og hvor meget har Medicare råd til ?

          1 Reply Last reply
          0
          • BulderB Offline
            BulderB Offline
            Bulder
            wrote on sidst redigeret af
            #78

            Klart nok. Erzo skal jo være et off the shelf produkt, helst i subkutan version, som med frontrunner i ryggen bliver godkendt til 1. linje på rekordtid. De der så relapser og bliver cd38 refraktære kan overgå til car-t, få komplet respons og leve fint til deres dages ende.

            1 Reply Last reply
            0
            • G Offline
              G Offline
              gentogen
              wrote on sidst redigeret af
              #79

              Måske. the pooled prevalence of relapse within the first 12 months after CAR-T infusion was 61%

              1 Reply Last reply
              0
              • G Offline
                G Offline
                gentogen
                wrote on sidst redigeret af
                #80

                Link Preview Image
                ScienceDirect

                favicon

                (www.sciencedirect.com)

                1 Reply Last reply
                0
                • BulderB Offline
                  BulderB Offline
                  Bulder
                  wrote on sidst redigeret af
                  #81

                  Nu er anitocaptagene ikke blandt dem du linker til. Dennes cr rate er flot, selv om den ikke er 100%. Mange vil kunne leve livet ud med MM efter cd38 og car-t.

                  1 Reply Last reply
                  0
                  • Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktør
                    wrote on sidst redigeret af
                    #82

                    Godmorgen 🙂

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Stroka
                      wrote on sidst redigeret af
                      #83

                      God morgen 🙂

                      1 Reply Last reply
                      0
                      • B Offline
                        B Offline
                        bibob
                        wrote on sidst redigeret af
                        #84

                        God morgen. 🙂

                        1 Reply Last reply
                        0
                        • P Offline
                          P Offline
                          ProinvestorNEWS
                          wrote on sidst redigeret af
                          #85

                          Genmab stiller med 20 indlæg ved ASH-konference https://proinvestor.com/investornyt/1238337/genmab-stiller-med-20-indlaeg-ved-ash-konference

                          1 Reply Last reply
                          0
                          • L Offline
                            L Offline
                            LP90
                            wrote on sidst redigeret af
                            #86

                            Godmorgen 🙂

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #87

                              Genmab to Highlight Epcoritamabs Promising Role in Non-Hodgkin Lymphoma Treatment at ASH Annual Meeting https://csimarket.com/news/genmab-to-highlight-epcoritamab-s-promising-role-in-non-hodgkin-lymphoma-treatment-at-ash-annual-meeting2024-11-06026109

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #88

                                Minhua Chu
                                @chuminhua432
                                ?? $ABBV AbbVie's BLA for epcoritamab (Epkinly) has been accepted by China's NMPA. https://x.com/chuminhua432/status/1854089849185460624

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #89

                                  same in chinese https://www.forbeschina.com/innovation/innovation/69032

                                  1 Reply Last reply
                                  0
                                  • L Offline
                                    L Offline
                                    lahn1
                                    wrote on sidst redigeret af
                                    #90

                                    Gentogen 17:29, er det data fra EPCORE DLBCL-1 ? kan ikke selv finde dem 🙂

                                    1 Reply Last reply
                                    0
                                    • L Offline
                                      L Offline
                                      lahn1
                                      wrote on sidst redigeret af
                                      #91

                                      EPCORE DLBCL-2 må det være ?

                                      1 Reply Last reply
                                      0
                                      • G Offline
                                        G Offline
                                        gentogen
                                        wrote on sidst redigeret af
                                        #92

                                        Ja: 581 Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial

                                        1 Reply Last reply
                                        0
                                        • G Offline
                                          G Offline
                                          gentogen
                                          wrote on sidst redigeret af
                                          #93

                                          Link Preview Image
                                          Paper: Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial

                                          favicon

                                          (ash.confex.com)

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper